Humacyte Shares Drop in Extended Session After Disclosing Stock Sale Plans

, MT Newswires -  4:22 PM ET 3/25/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

04:22 PM EDT, 03/25/2025 (MT Newswires) -- Humacyte ( HUMA ) shares slumped nearly 24% in after-hours activity late Tuesday after disclosing plans for an upcoming public offering of its common stock, subject to market and other conditions.

The biotechnology company did not indicate how many shares it expects to offer or other terms, although it expects to provide underwriters with a 30-day option to buy up to 15% more shares as overallotments.

The company plans to use the net proceeds from the offering to fund the commercialization of Symvess in the vascular trauma indication, the development of product candidates in its pipeline, and for working capital and general corporate purposes.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.